Abstract Details

Title USL255, Extended-Release Topiramate, Displays an Improved Pharmacokinetic Profile With Reduced Adverse Events Compared With Immediate-Release Topiramate

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) (-)

Poster/Presentation
Number 265

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Annie Clark PRESENTER	No disclosure on file
	No disclosure on file
Robert E. Hogan, MD (Washington Univ in St Louis/Neuro Dept)	Dr. Hogan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. The institution of Dr. Hogan has received research support from Biogen Inc. The institution of Dr. Hogan has received research support from Engage Therapeutics. The institution of Dr. Hogan has received research support from Otsuka Pharmaceuticals. The institution of Dr. Hogan has received research support from Cerevel Therapeutics.
Bob Anders	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details